Tecan Introduces Genesis Freedom Workstation

New Robotic Laboratory Workstation Delivers Unparalleled Flexibility and Freedom of Motion

 

Boston, MA -- The new Genesis Freedom workstation from Tecan is a modular, scalable, high-throughput system that allows researchers to automate complex processes in almost any workspace no matter how complex or confined.  It allows for the most comprehensive integration of genomics, proteomics and drug discovery laboratory research steps within a compact workstation footprint.

 

The highly flexible Genesis Freedom workstation is unique in its ability to accept up to three robotic arms.  It also has the industry's widest selection of robotic manipulators and accessories, which can be combined to create up to nine different arm configurations. The arms can access areas beyond the desktop, even underneath the workstation itself.  A small footprint allows for automated processes even in very confined areas.

 

Genesis and Genesis Freedom workstations deliver a totally integrated solution for automating the most diverse range of laboratory research applications from genomics and proteomics to drug discovery.

 

For genomics researchers faced with the daunting task of analyzing the vast quantities of information produced by sequencing the human genome, the Genesis Platform provides flexible solutions for automating and accelerating processes such as nucleic acid extraction and sample preparation, PCR setup, DNA normalization, genotyping and SNP scoring.  The Genesis Freedom workstation can also automate in situ hybridization for high-throughput gene expression and functional studies.  

 

In proteomics research applications, Genesis Freedom workstations are ideally suited for removing major bottlenecks by automating processes such as detection of unknown, low-abundant proteins, in-gel digestion, maldi spotting, and 2-D gel electrophoresis.

 

In drug discovery, the Genesis Platform of automated lab instrumentation and software covers the entire spectrum of drug discovery research applications, from early-stage compound synthesis, assay development, HTS, and Hit Picking, through ADME and toxicology assays.  This allows pharmaceutical and biotech companies to use human and material resources more efficiently, while optimizing the development cycle for new drugs.

 

Tecan is a leading player in the fast growing life sciences supply industry that specializes in the development, manufacturing, and distribution of enabling solutions for the discovery of pharmaceutical substances, as well as for genomics, proteomics, and diagnostics.  Founded in Switzerland in 1980, the company has manufacturing, research and development sites in both North America and Europe, and maintains a sales and service network in 52 countries.  Tecan clients are leading pharmaceutical companies, university research departments and diagnostic laboratories.  In 2000, Tecan achieved sales of CHF 273 million (USD 162 million: EUR 175 million).  Registered shares of Tecan Group are traded on the Swiss SWX stock exchange (TK:TECN / Reuters: TECZn.S / Valor: 707821).   

For further information, contact:

 

Tecan Boston

200 Boston Avenue
Medford, MA, 02155
Tel.: +1 (781) 306-0827
Fax: +1 (781) 306-0837
Internet: www.tecan.com

 

Elaine Y. Carraher
Global Mktg Comms Mgr, BioPharma
Tel.: +1 (781) 306-0827 x213
e-mail: elaine.carraher@tecan.com

 

THOMAS RANKIN ASSOCIATES

Thomas R. Rankin, APR
Tel.: +1 (401) 884-4090
e-mail: tomr@trankin.com

For more investor information, please contact:

 

Tecan Group Ltd.

Annabelle Brameshuber
Corporate Communications
Tel.: +41 (0)44 922 8430
e-mail: annabelle.brameshuber@tecan.com